Prelude Therapeutics Incorporated reported $22M of revenue over the trailing twelve months, +220% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $22M (to Q2 2026). Net income: −$60M, trailing twelve months to Q2 2026. Free cash flow: −$33M, trailing twelve months to Q2 2026. Operating margin: −301%, trailing twelve months to Q2 2026.

PRLDPrelude Therapeutics Incorporated

Healthcare

$3.88+169% 1Y

$3.88

$1.1952 weeks$6.62

PRLD as reported

Prelude Therapeutics Incorporated reported $22M of revenue over the trailing twelve months, +220% on the year before. 8 reported series are charted on this page, each one as filed.

$22M

Revenue, trailing twelve months · to Q2 2026 · +220% against the twelve months before

Net income: −$60M
Net income · −51% year on year · trailing twelve months to Q2 2026
Free cash flow: −$33M
Free cash flow · −69% year on year · trailing twelve months to Q2 2026
Operating margin: −301%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PRLD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$22M	+220%	Q2 2026
Net income	−$60M	−51%	Q2 2026
EPS	−$0.73	−55%	Q2 2026
Operating margin	−301%	n/a	Q2 2026
Net margin	−267%	n/a	Q2 2026
ROE	−128%	n/a	Q2 2026
ROA	−71%	n/a	Q2 2026
Free cash flow	−$33M	−69%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.